H
Hans K. Åkerblom
Researcher at University of Helsinki
Publications - 14
Citations - 1245
Hans K. Åkerblom is an academic researcher from University of Helsinki. The author has contributed to research in topics: Type 1 diabetes & Breastfeeding. The author has an hindex of 9, co-authored 14 publications receiving 1134 citations. Previous affiliations of Hans K. Åkerblom include Helsinki University Central Hospital.
Papers
More filters
Journal ArticleDOI
Tracking of Serum Lipid Levels, Blood Pressure, and Body Mass Index from Childhood to Adulthood: The Cardiovascular Risk in Young Finns Study.
Jonna Juhola,Costan G. Magnussen,Costan G. Magnussen,Jorma S. A. Viikari,Mika Kähönen,Nina Hutri-Kähönen,Antti Jula,Terho Lehtimäki,Hans K. Åkerblom,Matti Pietikäinen,Tomi Laitinen,Eero Jokinen,Leena Taittonen,Olli T. Raitakari,Markus Juonala +14 more
TL;DR: In this article, the authors examined tracking and predictiveness of childhood lipid levels, blood pressure, and body mass index for risk profile in adulthood and the best age to measure the childhood risk factor levels.
Journal ArticleDOI
Dietary intervention in infancy and later signs of beta-cell autoimmunity.
Mikael Knip,Suvi M. Virtanen,Karri Seppä,Jorma Ilonen,Erkki Savilahti,Outi Vaarala,Antti Reunanen,Kari Teramo,Anu-Maaria Hämäläinen,Johanna Paronen,Hans-Michael Dosch,Timo Hakulinen,Hans K. Åkerblom +12 more
TL;DR: Dietary intervention during infancy appears to have a long-lasting effect on markers of beta-cell autoimmunity--markers that may reflect an autoimmune process leading to type 1 diabetes.
Journal ArticleDOI
Hydrolyzed Infant Formula and Early β-Cell Autoimmunity: A Randomized Clinical Trial
Mikael Knip,Hans K. Åkerblom,Dorothy J. Becker,Hans Michael Dosch,John Dupre,William D. Fraser,N. J. Howard,Jorma Ilonen,Jeffrey P. Krischer,Olga Kordonouri,Margaret L. Lawson,Jerry P. Palmer,Erkki Savilahti,Outi Vaarala,Suvi M. Virtanen +14 more
TL;DR: Among infants at risk for type 1 diabetes, the use of a hydrolyzed formula, when compared with a conventional formula, did not reduce the incidence of diabetes-associated autoantibodies after 7 years, and these findings do not support a benefit from hydrolyzing formula.
Journal ArticleDOI
Study design of the trial to reduce IDDM in the genetically at risk (TRIGR)
TL;DR: The hypothesis for this study is that weaning to an extensively hydrolyzed infant formula will decrease the incidence of type 1 diabetes (T1D), as it does in all relevant animal models for the disease.
Journal ArticleDOI
The Trial to Reduce IDDM in the Genetically at Risk (TRIGR) study: recruitment, intervention and follow-up
TL;DR: TRIGR is the first ever primary prevention trial for type 1 diabetes and, if completed successfully, will provide a definite answer to the research question.